This stock will have a stealth bull run this year. The company is making progress building its business, slow and steady wins the race. There is a huge global market for a low-cost IVF alternative, and INVO has comparable pregnancy rates to traditional IVF. We could very well be at $1 by year-end if business momemtum picks up, particularly if the company secures funding for the U.S. FDA trial requested by the Agency for 510(k) clearance.